Turnbull, S, West, EJ, Scott, KJ et al. (3 more authors) (2015) Evidence for oncolytic virotherapy: Where have we got to and where are we going? Viruses, 7 (12). pp. 6291-6312. ISSN 1999-4915
Abstract
The last few years have seen an increased interest in immunotherapy in the treatment of malignant disease. In particular, there has been significant enthusiasm for oncolytic virotherapy, with a large amount of pre-clinical data showing promise in animal models in a wide range of tumour types. How do we move forward into the clinical setting and translate something which has such potential into meaningful clinical outcomes? Here, we review how the field of oncolytic virotherapy has developed thus far and what the future may hold.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
Keywords: | oncolytic virus; immunotherapy; reovirus; vaccinia; HSV; clinical trials |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 01 Feb 2016 12:52 |
Last Modified: | 12 Feb 2019 12:46 |
Published Version: | http://dx.doi.org/10.3390/v7122938 |
Status: | Published |
Publisher: | MDPI |
Identification Number: | 10.3390/v7122938 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:94267 |
Download
Filename: Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?.pdf
Licence: CC-BY 4.0